报价延迟最少15分钟:2025/07/20 16:59 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
10.42 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.42/-3.08
|
|
企业价值
730.62M
|
| 资产负债 |
|
每股账面净值
4.34
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
43.27M
|
|
每股收益
0.62
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/20 16:59 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S. |
